Suppr超能文献

年轻患者 Koos 分级 IV 型前庭神经鞘瘤的立体定向放射外科治疗:一项多机构研究。

Stereotactic radiosurgery for Koos grade IV vestibular schwannoma in young patients: a multi-institutional study.

机构信息

Department of Neurological Surgery, University of Virginia Health System, Charlottesville, VA, USA.

Department of Neurological Surgery, Hospices civils de Lyon, Lyon, France.

出版信息

J Neurooncol. 2022 Oct;160(1):201-208. doi: 10.1007/s11060-022-04134-0. Epub 2022 Sep 27.

Abstract

PURPOSE

Surgery is the treatment of choice for large vestibular schwannomas (VS). Stereotactic radiosurgery (SRS) has been suggested as an alternative to resection in selected patients. However, the safety and efficacy of SRS in Koos grade IV patients ≤ 45 years old has not been evaluated. The aim of this study is to describe the clinical and radiological outcomes of Koos grade IV in young patient managed with a single-session SRS.

METHODS

This retrospective, multicenter analysis included SRS-treated patients, ≤ 45 years old presenting with non-life threatening or incapacitating symptoms due to a Koos Grade IV VS and with follow-up ≥ 12 months. Tumor control and neurological outcomes were evaluated.

RESULTS

176 patients [median age of 36.0 (IQR 9) and median tumor volume of 9.3 cm (IQR 4.7)] were included. The median prescription dose was 12 Gy (IQR 0.5). Median follow-up period was 37.5 (IQR 53.5) months. The 5- and 10-year progression-free survival was 90.9% and 86.7%. Early tumor enlargement occurred in 10.9% of cases and was associated with tumor progression at the last follow-up. The probability of serviceable hearing preservation at 5- and 10-years was 56.8% and 45.2%, respectively. The probability of improvement or preservation of facial nerve function was 95.7% at 5 and 10-years. Adverse radiation effects were noted in 19.9%. New-onset hydrocephalus occurred in 4.0%.

CONCLUSION

Single-session SRS is a safe and effective alternative to surgical resection in selected patients ≤ 45 years old particularly those with medical co-morbidities and those who decline resection. Longer term follow up is warranted.

摘要

目的

手术是大型前庭神经鞘瘤(VS)的首选治疗方法。立体定向放射外科(SRS)已被提议作为某些患者切除的替代方法。然而,尚未评估年龄≤45 岁 Koos 分级 IV 患者的 SRS 的安全性和有效性。本研究旨在描述接受单次 SRS 治疗的年轻患者的临床和影像学结果。

方法

这项回顾性、多中心分析包括 SRS 治疗的患者,年龄≤45 岁,因 Koos 分级 IV VS 出现非危及生命或致残性症状,且随访时间≥12 个月。评估肿瘤控制和神经功能结局。

结果

176 例患者[中位年龄为 36.0(IQR 9),肿瘤体积中位数为 9.3cm(IQR 4.7)]被纳入。中位处方剂量为 12Gy(IQR 0.5)。中位随访时间为 37.5(IQR 53.5)个月。5 年和 10 年无进展生存率分别为 90.9%和 86.7%。10.9%的病例发生早期肿瘤增大,且与最后一次随访时的肿瘤进展有关。5 年和 10 年可保留听力的概率分别为 56.8%和 45.2%。5 年和 10 年面神经功能改善或保留的概率分别为 95.7%。19.9%的病例出现放射性不良反应。4.0%的患者出现新发脑积水。

结论

单次 SRS 是一种安全有效的替代手术切除的方法,适用于年龄≤45 岁的特定患者,特别是那些有合并症和拒绝手术的患者。需要更长时间的随访。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验